1
|
Omar AK, Ahmed KA, Helmi NM, Abdullah KT, Qarii MH, Hasan HE, Ashwag A, Nabil AM, Abdu AGM, Salama MS. The sensitivity of Na +, K + ATPase as an indicator of blood diseases. Afr Health Sci 2017; 17:262-269. [PMID: 29026401 DOI: 10.4314/ahs.v17i1.32] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Blood-related hereditary diseases are widespread in Eastern and SouthWestern regions of Saudi Arabia until recently. In this study, we used Na+, K+ATPase as an enzymatic indicator for the diagnosis of the diseases. MATERIALS AND METHODS Individuals with different blood diseases (iron deficiency (n=13), anemia (n=14), thalassemia (n=16) and sickle cell anemia (n=12) were studied for Na+, K+-ATPase activity in the plasma membrane of red blood cell and compared with those of the healthy ones (n=20) of the same age and gender living in Jeddah, Saudi Arabia. RESULTS There was a significant elevation in the specific activity of Na+, K+ATPase in individuals with anemia compared with those of control (0.0094 + 0.001 nmol / mg protein/min versus 0.0061 ± 0.001). On the other hand, there was a significant reduction in enzyme activity in thalassemia (0.0028 ± 0.002 nmol / mg protein/min) and sickle cell anemia cases (0.0042 ±0.001 nmol / mg protein/min) compared to the control group. The cut off value for Na+, K+ATPase activity is 0.005 µmol Pi/min-showing 94% sensitivity and 93% specificity for the differentiation of blood abnormality. CONCLUSION It can be recommended that the activity of Na+, K+-ATPase can be used for the diagnosis of individuals with blood diseases/disorders.
Collapse
Affiliation(s)
- Abulnaja Kkalid Omar
- Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
- Experimental Biochemistry unit, King Fahad Medical Research center (KFMRC), Jeddah, Kingdom of Saudi Arabia
- Bioactive Natural Products Research Group, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| | - Kherd Ali Ahmed
- Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| | - Nawal Mohammed Helmi
- Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
- Experimental Biochemistry unit, King Fahad Medical Research center (KFMRC), Jeddah, Kingdom of Saudi Arabia
| | - Kumosani Taha Abdullah
- Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
- Experimental Biochemistry unit, King Fahad Medical Research center (KFMRC), Jeddah, Kingdom of Saudi Arabia
- Production of bio-products for industrial applications Research group, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| | - Mohamad H Qarii
- Hematology Department, Faculty of Medical Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| | - Huwait Etimad Hasan
- Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| | - Albukhari Ashwag
- Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| | - Alaama Mohammed Nabil
- Consultant cardiologist, King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia
| | - Al-Ghamdi Maryam Abdu
- Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| | - Moselhy Said Salama
- Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
- Experimental Biochemistry unit, King Fahad Medical Research center (KFMRC), Jeddah, Kingdom of Saudi Arabia
- Bioactive Natural Products Research Group, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
- Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt
| |
Collapse
|
2
|
Biswas DK, Abdullah KT, Brennessel BA. On the mechanism of 5-bromodeoxyuridine induction of prolactin synthesis in rat pituitary tumor cells. J Cell Biol 1979; 81:1-9. [PMID: 479283 PMCID: PMC2111525 DOI: 10.1083/jcb.81.1.1] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
GH12C1, a clonal strain of rat pituitary tumor cells in culture (GH cells), does not produce detectable amounts of prolactin. 5-Bromodeoxyuridine (BrdUrd), the thymidine analogue, at sublethal concentrations (3-5 microgram/ml) induces prolactin synthesis in these cells. BrdUrd also induces prolactin synthesis in F1BGH12C1 cells, a BrdUrd resistant (BrdUrdr) substrain isolated from GH12C1 cells. The F1BGH12C1 strain is not drug dependent, but its resistance to BrdUrd is a stable phenotype. The significant features of the induction of prolactin synthesis in the BrdUrdr strain are the increased net synthesis of prolactin and the shortening of the lag period of prolactin induction. As BrdUrd concentration in the growth medium is increased, the rise in prolactin synthesis parallels the increased incorporation of BrdUrd into DNA. Prolactin synthesis is first detected when BrdUrd replaces 20-25% of the thymidine in DNA. BrdUrd can replace up to 75-80% of the thymidine within 2 d of treatment. Partial starvation of these cells under specified growth conditions does not affect the general growth pattern of the cells, general protein synthesis, and thymidine uptake, but does affect DNA synthesis. When cells are cultured under conditions in which DNA synthesis is preferentially inhibited, BrdUrd does not induce prolactin synthesis, suggestive of a DNA-mediated mechanism of action for the drug.
Collapse
|